Corbus shares fall as autoimmune drug fails another late-stage trial

Shares of Corbus Pharmaceuticals dropped Thursday on the news that its drug lenabasum has failed to effectively treat dermatomyositis in a late-stage trial. It’s the third late-stage trial failure in a year for the same drug.
Click here to view original post